When fixed doses of haloperidol or perphenazine were used in two separate studies, we found that psychotic males with a prior history of psychotogenic drug use had a poorer early neuroleptic response even in the early stages of their psychotic disorder than psychotic males who had not previously used significant amounts of psychotogenic drugs. Relative neuroleptic refractoriness may be characteristic of some dual diagnosis patients at the beginning of their illness. Antecedent psychotogenic drug use may contribute to the development of psychosis and to relative neuroleptic refractoriness by means of effects upon dopaminergic mechanisms.
It is becoming apparent that psychotogenic drug use may be a significant risk factor in a variety of psychotic disorders. Historically, a number of drugs have been observed to produce acute psychosis in a relatively clear sensorium in certain individuals, and some of these illnesses may be prolonged. It is now routine practice for clinicians to obtain a history of psychotogenic drug use that precedes the onset of a first psychotic episode. The initial motivations for such drug use are unclear as is the role drugs play in causing a psychotic episode to become manifest at a particular point in a patient's developmental history. More recently, periodic use of psychotogenic substances has been noted in the clinical histories of individuals suffering from chronic and relapsing psychotic disorders (Treffert 1978; Knudsen and Vilmar 1984) . This phenomenon has led to the designation of a dual diagnosis for these patients. Often they seem to be relatively young despite a lengthy period of illness and have been among the young adult chronic patients.
We have been interested in these issues for a number of years, since they are both clinically important and potential sources of new insights into the biological regulation of the expression of psychotic behavior. Initially, we focused upon motivations for drug use and upon certain phenomenological similarities between some apparent drugrelated psychoses and psychoses not associated with drug use (Bowers 1974) . We also compared these two classes of disorders on several biological and clinical items, including course of illness (Bowers 1972a (Bowers , 1972b (Bowers , 1977 , and investigated the relationship between a family history of major psychiatric disorder and psychotogenic drug use in a series of relatively young psychotic inpatients (Bowers and Swigar 1983) .
At the time of these earlier studies, the major psychotogenic drugs of abuse were cannabis and LSD (D-lysergic acid diethylamide). Subsequently LSD use in our patient population has been largely replaced by cocaine, while cannabis use has persisted. Our interest in how drug use affects the course of illness in psychotic disorders has continued, and an opportunity arose to examine this newer pattern of drug use in relation to early neuroleptic response in a group of patients with psychotic disorders of recent onset. Since dual-diagnosis Reprint requests should be sent to Dr. M.B. Bowers, Jr., Dept. of Psychiahy, Yile University School of Medicine, 25 Park St., New Haven, CT 06519.
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patients appear frequently to be relatively treatment refractory, we wanted to determine whether there was any evidence of differential neuroleptic response in these drugusing individuals early in the course of their illness.
Methods
Subjects were 35 consecutively admitted males under age 35 with acute psychosis. Males only were included because they are more likely to have used psychotogenic drugs at some point before the onset of a psychotic disorder. They were all participants in two separate fixeddose neuroleptic protocols. The haloperidol study preceded the perphenazine study. Age range was 15-32 years and DSM-III (American Psychiatric Association 1980) diagnoses were: schizophrenia-4, schizophreniform disorder-4, mania with psychosis-11, schizoaffective disorder-7, atypical psychosis-4, and depression with psychosis-5. No patient had received significant neuroleptic treatment within 1 week of admission, and all were actively psychotic. Twenty-two patients (mean age ± SD -24.3 ± 4 years) had a lifetime history of no or minimal psychotogenic drug use, rated 0-2 on a 5-point scale (0 « no use of psychotogenic substances, including cannabis; 4 => frequent cannabis use plus more than 10 episodes of cocaine use or other major psychotogenic drug oveT a period > 1 year). Thirteen patients (mean age ± SD = 226 ± 5 years) were scored as having a clearly significant history of drug use (rated 3 or 4).
Demographic and clinical data compared for the drug-use versus no-drug-use groups were as follows: number of prior hospitalizations, diagnosis, marital history, schizoidasocial developmental history, family history of major psychiatric disorder in a first-degree relative, significant suicidal ideation or attempt, and items on the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 1962) including depressed mood, guilt, excitement, suspiciousness, emotional withdrawal, and auditory hallucinations. None of these variables showed a significant difference between groups (table 1) .
Other variables thought relevant to response which were recorded and analyzed included the following: age, age of onset of psychotic symptoms, duration of the current episode, and levels of plasma free homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG). Fasting blood samples were drawn on the morning following hospital admission for measurement of HVA and MHPG (Bowers et al. 1984) .
Steady-state neuroleptic levels were also compared for each group (Bowers et al. 1989 ). In the no-druguse group, 8 patients received haloperidol (0.2 mg/kg/24 hours) and 14 received perphenazine (0.5 mg/kg/24 hours). In the drug-use group, five patients received haloperidol and eight received perphenazine. Benztropine was used for dystonic reactions and lorazepam was used for the management of agitation primarily in the first 3-4 days of the protocol. Global response was assessed at 10 days by two independent raters on a 4-point scale (0 •= no residual psychotic symptoms, 3 = no change or worse since admission). The response was the sum of these two ratings; all ratings were made without knowledge of plasma metabolite and serum neuroleptic concentrations.
For purposes of comparing the drug-use group and the no-drug-use group, continuous variables were evaluated using an unpaired t test and dichotomous variables by x 2 test. The interrelationships among early neuroleptic response, age, psychotogenic drug use, and plasma monoamine metabolites were assessed by Pearson's correlation coefficients.
Results
We found that the drug-use group had a significantly poorer early neuroleptic response than the nodrug-use group (t =• -2.09, p = 0.05). Only 2 out of 22 patients (9.0 percent) from the no-drug-use group had a poor response (global 4-6), whereas 7 out of 13 patients (53.8 percent) in the drug group had a poor response (x 2 = 6.38, df = 1, p -0.01). Table 2 shows the correlations between neuroleptic response, age, age at onset, drug use, and the plasma metabolites. Age and age at onset are significantly related to neuroleptic response (r = -0.49 and -0.50 respectively, p -0.001: the greater the age/age at onset, the better the response). Drug use is also significantly related to response as noted above (r » 0.46, p -0.003) as is plasma HVA (r = -0.42, p = 0.006: the higher the admission HVA, the better the response). HVA is also significantly correlated with drug use (r = -0.63, p •= 0.0001: the greater the use, the lower the HVA). HVA is not significantly related to age but is significantly associated with MHPG (r -0.34, p = 0.02).
To determine the relative association of variables to neuroleptic response, a stepwise multiple regression was performed using age, VOL. 16, NO. 1,1990 83 age at onset, HVA, and drug use as independent variables with neuroleptic response as the dependent variable. Both age at onset (/? = -0.48, p = 0.001) and HVA (/? = -0.40, p = 0.007) were significantly and independently associated with neuroleptic response, and accounted for 40 percent of the variance in the drug response score (F ' 10.43; df ° 2, 31; p = 0.0003). The addition of age or drug use did not add significantly to the total variance accounted for. The intercorrelation of drug use and HVA, coupled with the findings of the multiple regression, suggests the possibility that the relationship of drug use and response may be mediated by the drug's effect upon plasma HVA.
Plasma HVA was significantly higher in the no drug use group (table 3) . The two groups did not differ significantly in age, age of onset, or duration of the current episode. Steady-state haloperidol levels did not differ significantly in the two groups. There was a trend for lower steady-state perphenazine levels in the drug-use gTOup; however, our data and those of earlier investigators indicate that our mean level was still in the therapeutic range for perphenazine (Bolvig Hansen et al. 1982) .
Discussion
The primary aim of this study was to determine the relationship between a history of psychotogenic drug use and the response to neuroleptic treatment in relatively young male psychotic inpatients. The results indicate that such patients may, in fact, be more refractory to neuroleptic treatment even early in the course of their illness. This is a rather unexpected finding. Although drug use is commonly encountered as a risk factor in chronic psychotic patients who may be relatively refractory to neuroleptic treatment, it is somewhat surprising to find evidence that this characteristic may have been present from the onset of the disorder. One possible reason for this finding may be that common antecedent mechanisms contribute both to psychotogenic drug use and to relative neuroleptic refractoriness. For example, males with asocial development may be more likely to use drugs as a result of peer pressure, or some common neurobiological condition may lead to both drug use and poor neuroleptic response. It is interesting that the multiple regression indicates that drug use is no longer significantly associated with neuroleptic response after plasma HVA has been entered into the equation. Indeed, drug use and plasma HVA, but not MHPG, are significantly related. It is therefore possible to argue from our data that psychofogenic drug use may affect neuroleptic response adversely through an effect on a dopamine neuronal system that is reflected in plasma HVA. Without going into the arguments for relative central and peripheral contributions, and despite the modest significant correlation between plasma HVA and MHPG in our study, we believe it is unlikely that the source of the HVA in this context is the noradrenergic system, since neither drug use nor neuroleptic response is significantly related to plasma MHPG. It is possible to speculate that antecedent psychotogenic drug use may affect dopaminergic neurons in a lasting fashion. Both cocaine and cannabis, the drugs most commonly used by our subjects, affect dopaminergic transmission in animals. Cocaine appears to act by blocking dopamine reuptake (Nielsen et al. 1983) while cannabis promotes dopamine release (Bowers and Hoffman 1986) . The net effect would be increased synaptic dopamine concentration during periods of drug use. Decreased plasma HVA in the psychotic patients who had used drugs significantly might be related to reduced presynaptic dopamine synthesis secondary to excessive release. Another interesting possibility stems from the fact that these patients were already clearly vulnerable to the psychotogenic effects of these drugs. If this vulnerability were characterized by increased dopamine receptors in certain critical areas, then periodic drug use which enhanced synaptic dopamine might increase transmission excessively, leading to psychotic behavior. Reduced plasma HVA might then be seen as a compensatory presynaptic response. These notions are clearly speculative, but the relationship between drug use and plasma HVA in our study is provocative.
Much of the earlier literature dealing with drug use in relation to psychotic disorders focused upon the clinical comparison of psychotic subjects with and without antecedent drug use (Breakey et al. 1974; Tsuang et al. 1982; Vardy and Kay 1983) . The differences were not very dramatic, but predominant male sex, earlier onset, and better prognostic profiles were noted (for a review, see Bowers 1987) . Our current data are consistent with these general trends, but no differences are significant. The drug-use patients tended to be younger, more excited and suspicious, and less schizoid-asocial on developmental history. It is worth noting that druguse patients had a somewhat briefer onset period, still in excess of 6 weeks. Further, no significant group differences were noted in the percentage of patients who had a first-degree relative with a major psychiatric disorder requiring hospitalization.
In summary, using fixed-dose neuroleptic protocols, we have evidence that psychotic males with an antecedent history of psychotogenic drug use have, as a group, a poorer neuroleptic response compared to psychotic males who did not use drugs, even early in the course of their psychotic disorder. The contribution of drug use to response appears to be independent of age in this cohort but not independent of plasma HVA, which is also significantly related to neuroleptic response. Relative neuroleptic refractoriness may be characteristic of some dual-diagnosis patients at the beginning of their illness. Antecedent psychotogenic drug use may contribute to the development of psychosis and to relative neuroleptic refractoriness through effects upon dopaminergic mechanisms.
